Eisenstein T, Bushnell B, Meissler Jr J, Dalal N, Schafer R, HAVAS H
Med Oncol. 1995; 12(2):103-8.
PMID: 8535659
DOI: 10.1007/BF01676710.
Whittaker J
Br Med J. 1980; 281(6246):960-4.
PMID: 7000284
PMC: 1714324.
DOI: 10.1136/bmj.281.6246.960.
Ruhl H, Fulle H, Koeppen K, Schwerdtfeger R
Klin Wochenschr. 1981; 59(21):1189-93.
PMID: 6947118
DOI: 10.1007/BF01721213.
Ohno R, Yamada K, Masaoka T, Ohshima T, AMAKI I, Hirota Y
Cancer Immunol Immunother. 1984; 18(3):149-54.
PMID: 6391658
PMC: 11039289.
DOI: 10.1007/BF00205503.
Urbanitz D, Buchner T, Pielken H, van de Loo J
Klin Wochenschr. 1983; 61(19):947-54.
PMID: 6196515
DOI: 10.1007/BF01550267.
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
CURRIE G, McElwain T
Br J Cancer. 1975; 31(2):143-56.
PMID: 1164466
PMC: 2009407.
DOI: 10.1038/bjc.1975.19.
Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.
Sher N, Chaparas S, Greenberg L, Bernard S
Infect Immun. 1975; 12(6):1325-30.
PMID: 1107224
PMC: 415439.
DOI: 10.1128/iai.12.6.1325-1330.1975.
Granuloma formation in patients receiving BCG immunotherapy.
Whittaker J, Bentley D, Slater A
J Clin Pathol. 1976; 29(8):693-7.
PMID: 1066353
PMC: 476148.
DOI: 10.1136/jcp.29.8.693.
Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch P, DENT P, Blajchman M, Muirhead W, Price R
Can Med Assoc J. 1977; 117(1):33-6.
PMID: 861909
PMC: 1879633.
Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia.
Summerfield G, Gibbs T, Bellingham A
Br J Cancer. 1979; 40(5):736-42.
PMID: 389265
PMC: 2010104.
DOI: 10.1038/bjc.1979.254.
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
Powles R, Russell J, Lister T, Oliver T, WHITEHOUSE J, Malpas J
Br J Cancer. 1977; 35(3):265-72.
PMID: 322689
PMC: 2025283.
DOI: 10.1038/bjc.1977.38.
Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.
Schwarz M, Gutterman J, Hersh E, Richman S, Mavligit G
World J Surg. 1977; 1(5):555-83.
PMID: 272083
DOI: 10.1007/BF01556181.
Cytotoxic antibody in acute myeloblastic leukaemia during immunotherapy: lack of tumour specificity.
Gale D, MacLennan I
Br J Cancer. 1977; 35(3):280-7.
PMID: 265730
PMC: 2025282.
DOI: 10.1038/bjc.1977.40.
